Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
← catalyst calendarSponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
37actual
Sites
13
Countries
Israel, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision to terminate
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-15 | actual | When the study began enrolling |
| Primary completion | 2025-06-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-16 | actual | The whole study's end, after follow-up |
| First posted | 2021-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Malignancies
Interventions
- Drug: zamzetoclax — also filed as GS-9716
- Drug: Docetaxel
- Drug: sacituzumab govitecan-hziy
Primary outcomes
what the primary-completion date above is the date OFPercentage of Patients Experiencing Dose-Limiting Toxicities (DLTs)
measured First dose date up to 28 days
Percentage of Patients Experiencing Adverse Events (AEs) According to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), Version 5.0
measured First dose date up to last dose date (Maximum: 105 weeks) plus 30 days
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed